HEAL Study
Phase 2, Double-Blind, Placebo-Controlled Trial Of Topiramate For The Treatment Of Methamphetamine Dependence
Short Description
The objectives of this study are to assess the efficacy and safety of topiramate as compared to placebo in reducing methamphetamine use in subjects with methamphetamine dependence.
Release Date
Sep 02, 2015

The primary efficacy objective of this study is to determine if topiramate relative to placebo reduces methamphetamine use in subjects with methamphetamine dependence as measured by quantitative urinalysis for methamphetamine. The primary efficacy outcome measure is negative methamphetamine use weeks during study Weeks 6 through 12. Data collected during this phase of treatment will be the focus of the primary outcome measure as this is the time period in which the subject will be treated with the maintenance dose of topiramate.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
Study Links
Study Documents